World Health Organization (WHO) sought "additional clarifications" for Covaxin. The organization stated that they need clarifications from the manufactures to conduct a final Emergency Use Listing (EUL) risk-benefit evaluation for the global use of Bharat Biotech's Covaxin.
The technical advisory group will now assemble on November 3 for a final evaluation.So, the Technical Advisory Group for Emergency Use Listing (TAG-EUL) is an autonomous consulting group. This group advises WHO on whether a Covid 19 vaccine can be listed under the EUL mode for emergency use.
"The @WHO independent Technical Advisory Group (TAG) met today & asked for additional clarifications from the manufacturer @BharatBiotech to conduct a final EUL risk-benefit assessment for global use of #Covaxin. In a tweet, it will reconvene for the final assessment on Wednesday, November 3, if data is received soon," WHO chief scientist Dr Soumya Swaminathan declared.
Bharat Biotech submitted data to WHO on a rolling basis. They also submitted a supplementary report at the UN health body's call on September 27.
Covaxin is the nation's first indigenous COVID-19 vaccine. It was developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research.
The Covaxin has explained 77.8% effectiveness against symptomatic COVID-19. Moreover, 65.2% protection against the new Delta variant.
In June, the company stated it ended the final examination of Covaxin efficiency from Phase 3 trials. Bharat Biotech's Covaxin and AstraZeneca, and Oxford University's Covishield are extensively used vaccines in India.
The WHO has recommended Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India. They have also recommended the use of Johnson & Johnson-Janssen, Moderna, and Sinopharm for emergency treatment.